Jasjit Walia, MD
Cardiovascular Disease · Elizabeth, NJNPI 1477573814
Payments from drug & device makers
Across 533 payments — averaging $1611.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$692K
- Eli Lilly$89K
- Bayer$51K
- E.r. Squibb & Sons, L.L.C.$12K
- Angiodynamics, Inc.$7K
- AstraZeneca$2K
- plus $7K from 29 others
Across 3 payments — averaging $688.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Food & beverage$8,20254%
- Education$6,68844%
- Other$2111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 34 | $692,111 |
| Eli Lilly | 5 | $88,735 |
| Bayer | 11 | $51,189 |
| E.r. Squibb & Sons, L.L.C. | 51 | $12,019 |
| Angiodynamics, Inc. | 1 | $6,688 |
| AstraZeneca | 102 | $1,674 |
| Novo Nordisk | 117 | $1,441 |
| Amgen | 6 | $1,310 |
| Abbott | 24 | $634 |
| Pfizer | 29 | $427 |
| Lilly USA, LLC | 29 | $427 |
| Boehringer Ingelheim | 17 | $367 |
| Merck | 24 | $355 |
| GSK | 19 | $281 |
| Merit Medical Systems Inc | 1 | $211 |
| Heartflow, Inc. | 10 | $188 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $184 |
| Johnson & Johnson | 11 | $156 |
| Boston Scientific | 3 | $156 |
| Amarin Pharma, Inc. | 9 | $117 |
| Medtronic(2 entities) | 2 | $97 |
| Cardinal Health 200 LLC | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Cvrx, Inc. | 1 | $28 |
| Exact Sciences | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Cleerly, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| AbbVie | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
| Axsome Therapeutics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$6,688
- CAMZYOS$260
- FARXIGA$127
- WATCHMAN Access System$125
- ELIQUIS$125
- JARDIANCE$125
How this compares
$859,057 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 610 | $794,186 |
| MounjaroTirzepatide | 356 | $442,478 |
| OzempicSemaglutide | 349 | $420,655 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 251 | $271,168 |
| FarxigaDapagliflozin Propanediol | 224 | $235,951 |
| JardianceEmpagliflozin | 129 | $178,141 |
| EntrestoSacubitril/Valsartan | 137 | $175,070 |
| XareltoRivaroxaban | 120 | $117,415 |
| TrulicityDulaglutide | 79 | $115,557 |
| LinzessLinaclotide | 102 | $114,241 |
| JanuviaSitagliptin Phosphate | 84 | $110,231 |
| BrilintaTicagrelor | 106 | $109,611 |
| RybelsusSemaglutide | 19 | $43,032 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $42,664 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $38,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $427 | $828,295644 claims |
| Lilly USA, LLCMounjaro, Trulicity | $427 | $558,034435 claims |
| Novo NordiskOzempic, Rybelsus | $1,441 | $463,687368 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere, Symbicort | $1,674 | $399,593394 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $281 | $291,157282 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta | $367 | $249,525186 claims |
| NovartisEntresto | $692,111 | $175,070137 claims |
| MerckJanuvia, Janumet, Verquvo | $355 | $171,446137 claims |
| Johnson & JohnsonXarelto | $156 | $117,415120 claims |
| AbbVieLinzess | $15 | $114,241102 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $184 | $38,29512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Elizabeth
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Sajjad SabirCamden$742K
- John CovaleskyManalapan$716K
- Sanford GipsHaddon Heights$668K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.